ERCC5 is a novel biomarker of ovarian cancer prognosis

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 2952-2958

  Walsh, Christine S ^a   Ogawa, Seishi ^a   Karahashi, Hisae ^a   Scoles, Daniel R ^a   Pavelka, James C ^a   Tran, Hang ^a   Miller, Carl W ^a   Kawamata, Norihiko ^a   Ginther, Charles ^a   Dering, Judy ^a   Sanada, Masashi ^a   Nannya, Yasuhito ^a   Slamon, Dennis J ^a   Koeffler, H Phillip ^a   Karlan, Beth Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN ERCC5; RNA; TUMOR MARKER; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC 5; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; NUCLEAR PROTEIN; PLATINUM COMPLEX; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER SURGERY; CHROMOSOME 13Q; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DNA ADDUCT; DNA ISOLATION; DNA MICROARRAY; DNA REPAIR; DOWN REGULATION; ERCC5 GENE; EXCISION REPAIR; FEMALE; GENE; GENE EXPRESSION; GENE LOCUS; GENOME; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RNA ISOLATION; SURVIVAL TIME; TREATMENT RESPONSE; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 46449089448     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5806     Document Type: Article

References (32)

1. McGuire WP 3rd, Markman M: Primary ovarian cancer chemotherapy: Current standards of care. Br J Cancer 89:S3-S8, 2003 (suppl 3)
2. Högberg T, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40:340-360, 2001
3. Piccart MJ, Lamb H, Vermorken JB: Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12:1195-1203, 2001
4. Harries M, Kaye SB: Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 10:1715-1724, 2001
5. Giaccone G: Clinical perspectives on platinum resistance. Drugs 59:9-17, 2000 (suppl 4)
6. Nannya Y, Sanada M, Nakazaki K, et al: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079, 2005
7. Samec S, Clarkson SG, Blaschak J, et al: Dinucleotide repeat polymorphism within ERCC5 gene. Hum Mol Genet 3:214, 1994
8. Kennedy RD, D'Andrea AD: DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24:3799-3808, 2006
9. Kelland LR: Preclinical perspectives on platinum resistance. Drugs 59:1-8, 2000 (suppl 4)
10. Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478:23-43, 2001
11. Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer 1:22-33, 2001
12. Park CJ, Choi BS: The protein shuffle: Sequential interactions among components of the human nucleotide excision repair pathway. Febs J 273:1600-1608, 2006
13. Dunand-Sauthier I, Hohl M, Thorel F, et al: The spacer region of XPG mediates recruitment to nucleotide excision repair complexes and determines substrate specificity. J Biol Chem 280:7030-7037, 2005
14. O'Donovan A, Davies AA, Moggs JG, et al: XPG endonuclease makes the 3′ incision in human DNA nucleotide excision repair. Nature 371:432-435, 1994
15. Wakasugi M, Reardon JT, Sancar A: The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem 272:16030-16034, 1997
16. Constantinou A, Gunz D, Evans E, et al: Conserved residues of human XPG protein important for nuclease activity and function in nucleotide excision repair. J Biol Chem 274:5637-5648, 1999
17. Hanawalt PC: Controlling the efficiency of excision repair. Mutat Res 485:3-13, 2001
18. States JC, Reed E: Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett 108:233-237, 1996
19. Ferry KV, Hamilton TC, Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF. Biochem Pharmacol 60:1305-1313, 2000
20. Yu JJ, Bicher A, Ma YK, et al: Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues. Cancer Lett 151:127-132, 2000
21. Dabholkar M, Bostick-Bruton F, Weber C, et al: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992
22. Selvakumaran M, Pisarcik DA, Bao R, et al: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63:1311-1316, 2003
23. Furuta T, Ueda T, Aune G, et al: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899-4902, 2002
24. Köberle B, Masters JR, Hartley JA, et al: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9:273-276, 1999
25. Takebayashi Y, Nakayama K, Kanzaki A, et al: Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: Implication for their roles of carcinogenesis in human solid tumors. Cancer Lett 174:115-125, 2001
26. Yang-Feng TL, Li S, Han H, et al: Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer 52:575-580, 1992
27. Shivji KK, Kenny MK, Wood RD: Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374, 1992
28. Koeppel F, Poindessous V, Lazar V, et al: Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res 10:5604-5613, 2004
29. Skotheim RI, Autio R, Lind GE, et al: Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol 28:315-326, 2006
30. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320, 2005
31. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23, 2007
32. Wernyj RP, Morin PJ: Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel. Drug Resist Updat 7:227-232, 2004